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Abstract: Obesity is one of the most prevalent health conditions in humans and companion animals
globally. It is associated with premature mortality, metabolic dysfunction, and multiple health
conditions across species. Obesity is, therefore, of importance in the fields of medicine and veterinary
medicine. The regulation of adiposity is a homeostatic process vulnerable to disruption by a multitude
of genetic and environmental factors. It is well established that the heritability of obesity is high in
humans and laboratory animals, with ample evidence that the same is true in companion animals.
In this review, we provide an overview of how genes link to obesity in humans, drawing on a wealth of
information from laboratory animal models, and summarise the mechanisms by which obesity causes
related disease. Throughout, we focus on how large-scale human studies and niche investigations of
rare mutations in severely affected patients have improved our understanding of obesity biology and
can inform our ability to interpret results of animal studies. For dogs, cats, and horses, we compare
the similarities in obesity pathophysiology to humans and review the genetic studies that have been
previously reported in those species. Finally, we discuss how veterinary genetics may learn from
humans about studying precise, nuanced phenotypes and implementing large-scale studies, but also
how veterinary studies may be able to look past clinical findings to mechanistic ones and demonstrate
translational benefits to human research.
Keywords: obesity; genetics; companion animals; metabolic disease; comparative genomics; dogs;
cats; horses
1. Introduction
Obesity presents a major health problem in humans and companion animals alike. An estimated
39% of people were overweight or obese in 2016, a value nearly triple that recorded in 1975 and
equating to over 2 billion adults [1]. Mirroring that trend are increases in pet obesity, with as many
as 63% of cats [2] and 59% of dogs [3] reported to be overweight or obese. Obesity was declared an
epidemic by the World Health Organisation (WHO) in 1997 [4] and similarly identified as a major
threat to pet health by BSAVA and WSAVA [5].
Precise definitions of obesity are debated, but it is generally accepted that obesity is the unhealthy
accumulation of body fat. What is not controversial is that obesity is a consequence of energy
intake chronically exceeding energy output. Consequently, obesity has commonly been considered
a ramification of poor self-control in people or of inept management by animal owners. However,
considerable evidence now shows obesity is better regarded as a disease of disordered energy
homeostasis in which a multitude of genetic and environmental factors can contribute to increasing
body fat.
This review first examines the pathophysiology of obesity and the role of genetics in the disease,
focussing on the wealth of evidence from human and rodent studies. We then review the genetics
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of obesity and related metabolic disease in companion animals. Finally, we consider opportunities
for future research in companion animals that may improve understanding of both animal and
human obesity.
2. Factors Contributing to Obesity
Recent, rapid increases in the prevalence of obesity have been caused by changes in activity
and diet in the human population, and the same is likely true in animal populations [6,7]. However,
it is clear that, although much of the human population is exposed to an “obesogenic environment”
(with ready access to high calorie food and increasingly sedentary lifestyles), only a subset become
overweight or obese. It is now well established that multiple factors including socioeconomic status,
education level, and genetics are associated with whether a person is likely to develop obesity [8].
In companion animals, similarly diverse risk factors have been identified, with biological factors
such as age, sex, and breed recognised alongside owner management factors in dog, cat, and horse
obesity [9–12].
Acknowledgement of the multiple obesity risk factors is important, because it informs efforts
to reduce obesity. Stigma against overweight people and parents of overweight children is well
recognised [13,14], and the same is true for owners of overweight companion animals [15,16].
Such stigmas arise from the widespread view that weight gain is due to lax efforts to regulate
food intake and exercise, either by a person, parent, or animal owner. It is important to acknowledge
the risk factors beyond an individual’s control (such as genetics) in order to improve the effectiveness
of obesity prevention and treatment programmes.
Obesity Susceptibility Is Highly Heritable
Humans within the same environment, be that energy surplus or energy scarcity, display a highly
heritable variance in body condition [17]. A wealth of data from twin and adoption studies, bolstered
by later estimates of chip heritability in the era of high-density genotyping, supports that human
obesity, indicated by body mass index (BMI), is a highly heritable trait. Heritability estimates range
from 71–81% [17–19]. However, despite intensive efforts, the genes and mutations responsible for the
majority of this heritability remains to be elucidated.
3. Studies of Monogenic Obesity Have Been Highly Informative
Obesity is usually a complex trait, with many genomic loci contributing incrementally to modulate
an individual’s susceptibility. However, monogenic forms of obesity also exist with patients usually
coming to attention, because they develop severe obesity early in life. Interrogating the genetics
of these rare patients, in combination with research in rodent and cellular models, has been hugely
informative in elucidating the molecular basis of the regulation of energy homeostasis and body weight.
Early studies of patients with monogenic forms of obesity focussed on candidate genes chosen based
on information from rodent models of obesity [6].
3.1. The Discovery of Leptin
In 1950, a rodent model demonstrating severe obesity was identified, and the gene responsible
named the obesity (ob) gene [20]. A similar obesity phenotype due to a different gene was discovered
in diabetic mice, named the diabetes (db) gene [21,22]. Subsequent parabiosis experiments in which
mice of contrasting genotype were surgically joined to share a circulation led to the conclusion that
ob/ob mice lacked a circulating factor that controls eating behaviour, whereas db/db mice possessed such
a factor but were not able to respond to it [23,24]. In 1994, the circulating factor was pinpointed and its
function delineated; a hormone called leptin, which is secreted from fat cells [25]. The ob and db genes
were subsequently identified as the genes for leptin (Lep) and its receptor (Lepr), respectively.
Shortly afterwards, a frameshift mutation in the human leptin gene (LEP) [26] was identified
in children with severe, early-onset obesity. The mutation caused congenital leptin deficiency that
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was successfully treated with recombinant leptin therapy (See Figure 1). Since this, many more
severely obese individuals have been identified with mutations in LEP [27–29] and provided help with
recombinant leptin. Such studies clearly justify the importance of genetic research and its translational
significance for prevention and treatment of disease.
Patients with mutation in the human leptin receptor gene (LEPR) [30–32] who display extreme
obesity have also been identified. However, recombinant leptin treatment in these patients is entirely
ineffective, since they suffer from leptin resistance as opposed to leptin deficiency [33–35].
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3.2. The Leptin–Melanocortin Pathway
We now understand that the primary effector mechanism for leptin’s action is in the central nervous
system (CNS), where it activates the hypothalamic leptin–melanocortin pathway [37], a neuroendocrine
signalling mechanism, which transmits a signal about the status of the body’s energy reserves to the brain
and translates it into effector signals to promote optimal energy balance. In summary (See Figure 2),
the hormone leptin is produced and released from adipose tissue. In the insulin-dependent fed
state, insulin stimulates leptin release, and in greater amounts when energy reserves (in the form
of fat stored in adipocytes) are larger [38,39]. In the brain, leptin acts on receptors in the arcuate
nucleus (ARC) of the hypothalamus to activate proopiomelanocortin (POMC) neurons to produce the
pre-pro-protein proopiomelanocortin (POMC). POMC undergoes proteolytic cleavage to produce a
number of neuroactive peptides, the most important of which in regulating energy homeostasis are
α- and β- melanocyte stimulating hormone (α-MSH, β-MSH). MSH peptides act on melanocortin
receptor 4 (MC4R) expressed on second-order neurons of the paraventricular nucleus (PVN) of the
hypothalamus, resulting in reduction in food intake and modified energy metabolism by interaction
with multiple other pathways [17,40].
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3.3. Disruption of Leptin–Melanocortin Signalling Leads to Obesity
Mutations that disrupt the leptin–melanocortin pathway are associated with severe obesity in
both rodents and humans [41,42]. Dominant mutations in the proopiomelanocortin gene (POMC) are
reported to cause severe, early-onset obesity in affected patients, often with other neuroendocrine
features consistent with the diverse physiological roles of the multiple POMC-derived peptides [43–46].
Similarly, obesity has been reported due to mutations affecting prohormone convertase 1 gene (PCSK1),
one of the enzymes responsible for proteolytic cleavage of POMC to its neuroactive derivatives,
either singly or as part the more complex genetic condition Prader–Willi Syndrome [47].
Variants residing in the gene SIM1 have also been associated with severe obesity and
Prader–Willi-like syndromes [48,49], an effect attributed to this transcription factor’s integral role in
development of the PVN, a hypothalamic nucleus, which is most notable as the major site of MC4R
expression [48].
More common are mutations in the MC4R gene, which have been shown to cause both dominant
and recessive forms of monogenic obesity [50–53] and are responsible for up to 6% of severe, early-onset
obesity cases [46,54–56]. More recently, MC4R variants with less severe effects on receptor function
have been shown to be major modifiers of obesity risk in the wider human population [57–59]. Notably,
those data show that the genetic background against which the MC4R mutation occurs has a large
influence on the penetrance of the obesity phenotype.
3.4. Other Causes of Monogenic Obesity
Variants affecting other biological pathways have also been identified as monogenic causes of
obesity, with the majority related to CNS regulation of energy metabolism. Semaphorin 3 gene (SEMA3)
variants are rare causes of severe early-onset obesity and affect energy balance through their role in
melanocortin neuron development [60]. Brain-derived neurotrophic factor (BDNF) acts on its receptor
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tropomyosin receptor kinase B (TRKB), and there is increasing evidence that this signalling plays
a significant role in sustaining equilibrium of energy balance in the brain [61]. Mutations affecting
the concordant protein-coding genes (BDNF/TRKB) have been reported as causes of monogenic
human obesity.
It is noteworthy that all the aforementioned variants primarily modify eating behaviour.
The exception to this came with the discovery that rare variants in the Kinase suppressor of Ras 2
gene (KSR2) appear to cause obesity by affecting both energy intake and energy expenditure (although
primarily via affecting the central control of energy metabolism) [62]. Reminiscent of this, a CREBRF
variant that is common in Samoans but very rare in other populations, appears to be a major modifier
of obesity risk by altering energy use in the body [63].
4. Common Human Obesity
Although cases of monogenic obesity exist, they account for only 5–7% of severe obesity cases [17,
54,64] and much less of the obesity that develops later in life. Common obesity is a complex trait,
caused by the additive effect of hundreds, possibly even thousands, of common genetic variants [65].
Genome-wide association studies (GWAS) have provided valuable insight into which loci, genes,
and variants are responsible. Large, consortium-based studies involving hundreds of thousands of
human subjects have been performed on quantitative traits such as BMI (the best available indicator of
body fat percentage for large scale studies) and obesity-related traits such as waist-to-hip ratio (WHR,
an indicator of where an individual’s body fat is stored) and measures of insulin resistance (and related
metabolites), leading to identification of hundreds of quantitative trait loci [66] for obesity and related
traits across the genome [66–71].
Despite those successes, just 3–5% of obesity heritability is explained by existing GWAS data [72].
The “missing heritability” of obesity [72,73] is hypothesised to be due to large effect rare variants yet to
be identified: many loci of small/moderate effect too common to find with GWAS; non-additive genetic
effects; and copy number variants (CNVs); among others [73–76]. Of those, the large-effect rare variant
is particularly relevant to those studying veterinary species—selective breeding may lead to enrichment
of variants of large effect within a breed, which are otherwise rare across the species overall [77].
Notably, an expanding body of evidence implicates the microbiome in obesity pathophysiology,
and obesity-associated gut microbiota populations have been shown to be heritable [78]. Thus, an
individual’s microbiome may also account for a fraction of the heritable component.
Nonetheless, identified obesity-associated loci can be used to generate estimates of individuals’
risk of developing obesity, known as polygenic risk scores (PRS), whereby a weighted effect score is
generated as the product of allele count and effect score for risk variants. PRS have been proposed as
clinical tools although their application is currently limited [79,80], in part because there is evidence
that their validity may be limited in ethnic groups other than that in which they were originally derived.
Nonetheless, PRS have been shown to be effective measures with which to stratify genetic obesity risk
across a population, as in Figure 3. They have also improved our understanding of how background
polygenic risk can alter trait penetrance in the presence of mutations with moderate–large effect on the
trait, such as in MC4R [57], mentioned above.
From GWAS to Function
Notably, a large proportion of genes implicated by human obesity GWAS are preferentially
expressed in the CNS [67,81], providing further evidence for the critical role of the brain in controlling
energy homeostasis. Many genes implicated in monogenic obesity have also been flagged in these
large-scale obesity GWAS, including LEPR, MC4R, and POMC, although they are usually not the most
prominent findings [67,82].
Moving from GWAS-associated locus to identify causative variants and their mechanisms of
action is difficult. Some of the most common obesity-associated loci identified lack clear mechanisms by
which variants exert their effects. A notorious example of this is the repeated and robust association of
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BMI with genetic variants lying within an intron of FTO α-ketoglutarate-dependent dioxygenase gene
(FTO) also known as fat-mass- and obesity-associated gene (in mice). Those findings led to extensive
efforts to characterise the role of this gene and provide evidence that FTO plays a part in regulating
food intake. However, it later transpired that the focus on the closest gene was inappropriate and that
obesity association for this locus is, at least in large part, due to altered regulation of a neighbouring
gene, iroquois homeobox 3 (IRX3), which has an impact on peripheral adipocyte metabolism [83].
Although those findings have been challenged [84,85], it remains an example of how complex it has
been to move from BMI locus to novel obesity biology.
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5. Genetic Insight into Obesity Comorbidities and Metabolic Syndrome
Obesity exerts a huge toll on human health due to its attendant comorbidities including type 2
diabetes mellitus (T2D), cardiovascular disease (CVD), stroke, and non-alcoholic fatty liver disease
(NAFLD), among others [86–88]. Development of these comorbidities is largely mediated by a
constellation of clinical features commonly referred to as “metabolic syndrome” that include raised
blood pressure, dyslipidaemia, increased triglycerides, and insulin resistance [89,90].
However, it is recognised that the severity of obesity does not necessarily correlate with the
onset or severity of metabolic syndrome, and that some people remain metabolically healthy despite
severe obesity [91–93]. Those differences occur not just between individuals but also between ethnic
groups, leading to different recommended cut-offs for what is regarded as a “healthy” BMI in different
populations. For example, a WHO expert consultation considered alternative BMI “cut-offs” in
Asian populations given their high risk of T2D and CVD at BMIs considerably lower than previously
recommended [94].
How obesity leads to its comorbidities has been intensively studied in humans and model
organisms, informed by genetics. For instance, the relationship between obesity and T2D is reinforced
by the presence of vertical pleiotropy with shared loci implicated in GWAS for both T2D and BMI.
The causal relationship between obesity and its complications has been confirmed by Mendelian
randomisation studies [95]. Similar suggestions and confirmation of cause and effect come from GWAS
and Mendelian randomisation studies of BMI/insulin resistance and NAFLD [96].
More nuanced mechanistic insight has come from the study of rare patients with severe, early-onset,
monogenic forms of insulin resistance. Studies of rare patients with mutations affecting the insulin
receptor (INSR) or which interrupt signalling downstream of it have provided insight into the
pathogenesis of insulin resistance and consequent dyslipidaemia or hepatic lipid accumulation in
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common obesity [93]. For instance, common variants in the gene encoding insulin receptor substrate
1 (IRS1), an important component of the intracellular signalling pathway, are associated with T2D,
most likely by making affected individuals more susceptible to developing obesity-associated insulin
resistance [97].
Similar value came from the study of patients with lipodystrophy, a rare condition in which there
is complete or partial absence of adipose tissue. Recognition that the absence of fat was associated with
early and severe insulin resistance and features of metabolic syndrome was central to establishing that
the ability to store fat is critical to maintenance of normal metabolic function [98]. Those conclusions
were later supported by analysis of genetic determinants of insulin resistance in the wider population,
which provided evidence that variation in susceptibility to obesity co-morbidities are in part due to
variation in individuals’ ability to develop and maintain healthy fat storage depots [70].
Overview—Molecular Mechanisms Underlying Obesity Co-Morbidities
Together, human genetic studies and those in cell and animal models mean we now understand
much more about how obesity causes disease. Much of those data support the theory of “limited
adipose expandability”. In brief summary, it appears that the body can accumulate fat in a healthy
manner only until it reaches the limit of adipose tissue’s ability to expand. Subsequently, adipose
tissue dysfunction leads to inflammation and increased lipid flux, which in turn leads to ectopic lipid
accumulation in non-adipose organs such as the liver and muscles. Combined with local and systemic
inflammation, this leads to widespread insulin resistance, which in turn, results in increased insulin
demand as the body attempts to maintain glucose homeostasis. Initially, insulin-producing β cells in the
pancreas meet this demand but ongoing insulin resistance and ectopic lipid deposition in the pancreas
itself can ultimately lead to β cell failure, hyperglycaemia, and T2D. Simultaneously, the altered lipid
flux leads to dyslipidaemia and multiple mechanisms converge to cause hypertension [99,100].
Whether an individual develops obesity-associated co-morbidities may therefore be influenced
by genes at many levels: a genetic predisposition to weight gain increases the chance of obesity
developing; the ability to develop and maintain healthy fat stores appears to differ between individuals
and across ethnic groups; if variants that perturb insulin signalling are present, they may promote the
development of insulin resistance; and genes may also influence the ability of β cells to respond with
adequate insulin where resistance develops. Consequently, in common disease, it is the net effect of
many variants affecting such systems, combined with environmental influences, which determines
whether obesity-related comorbidities develop.
6. Applying Current Knowledge to Study Companion Animal Disease
It is well established that obesity and its sequelae are heritable traits in humans and laboratory
animals. The majority of obesity genes affect central regulation of food intake but notable examples
whereby genes affect energy expenditure do exist. Genetic variance in susceptibility to obesity
co-morbidities is well established and can be due to effects on a variety of body systems and processes.
Importantly, this wealth of information is available to inform investigations into companion
animal disease. However, there is much yet to learn, and it is equally true that study of spontaneously
occurring, companion animal models of obesity is a potentially valuable way to learn new biology
relevant to all species. To date, studies of the molecular basis of obesity and associated disease remain
limited in companion animals, with the predominance of small-scale and candidate genes studies
somewhat limiting their value.
Available evidence suggests much commonality in the pathophysiology of obesity between
humans, dogs, cats, and horses, but there are important differences in the incidence and severity of
obesity-related co-morbidities between companion animal species, which likely reflect fundamental
differences in physiology. Below, we consider in sequence the studies performed in dogs, cats, and
horses to investigate the genetic basis of weight gain and, where relevant, obesity-related disease.
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7. Canine Obesity Genetics
An estimated 34–59% of pet dogs in developed countries are overweight or obese [3,9,101–104].
Multiple comorbidities are associated with canine obesity, most notably: orthopaedic disease,
exacerbation of breathing difficulties, and urinary incontinence, along with significantly decreased life
expectancy [105–108]. Canine obesity is associated with increased blood pressure, dyslipidaemia, and
insulin resistance, and this has been characterised as “obesity-related metabolic dysfunction” [109,110].
There is also some epidemiological evidence that obesity is a risk factor for developing canine, but this is
not a recognised problem in clinical practice diabetes [111]. Other human obesity-related complications
such as CVD and NAFLD do not have equivalent recognised presentations in canine practice. As with
humans, studies suggest that weight loss leads to normalisation of many of the associated metabolic
perturbations in dogs [109].
Evidence for the role of genetics in governing canine obesity susceptibility comes from the fact that
obesity prevalence differs dependent on breed, with some breeds predisposed (e.g., Labrador retrievers,
pugs, golden retrievers) and others resistant (e.g., greyhounds, whippets) [10,112,113]. Concordantly,
differences in eating behaviour and food preference between breeds have been shown [114,115].
Although some of the variation in obesity susceptibility between breeds could be down to
differences in “fashion” for each breed, the repeated finding of breed as a risk factor for obesity means
genetic determinants are more likely the cause. Such variation in trait susceptibility between breeds is
common in dogs due to the species’ unusual population architecture in which there is high diversity as
a whole combined with high homogeneity within breeds, the product of population bottlenecks at
breed formation and subsequent intensive selection for breed-specific traits [116–118]. Heritability of
canine obesity is yet to be determined, but some have speculated that it will be reminiscent of high
estimates in humans and other animal species [119–122].
The genetic basis of body mass has been investigated using GWAS in dogs, but those results
cannot be regarded as indicative of obesity because of the wide variability in body morphology breeds.
Instead, those study results likely better reflect the combination of height, length, musculature, and
limb: trunk ratio [123].
To date, no GWAS of canine fat mass or related traits have been reported. In part, this may be
related to the difficulty of accurately phenotyping obesity in dogs; the aforementioned wide variety
of skeletal size and shape in dogs precludes using simple and commonly available measures such as
weight to estimate fat mass. Quantification of adiposity can be done using sophisticated imaging or
biochemical techniques, electrical impedance or ultrasound measurement of fat deposits, but those
cannot practically be applied in large cohorts [124]. The clinically widely used and well-validated
alternative is to assign dogs a “body condition score” (BCS). This should be performed by a veterinary
professional who uses a variety of haptic and visual clues to assign dogs to one of a series of ordinal
scores. The most widely used 9-point scale [125] has been thoroughly validated [124,126] such that
each one point increase in BCS above “normal” equates to approximately 10% increase in fat mass.
A 5-point scale is also available and has been reported in some of the studies below.
7.1. Genes Investigated in Canine Obesity
Several candidate gene studies have been performed in domestic dogs and closely related, farmed
Canidae species. The merit of looking at genetic factors in other Canidae species is arguable, but they
are reported here, since previous studies have found them relevant. The best characterised of the
later mentioned studies are the ones that have considered genes implicated in the leptin–melanocortin
signalling pathway. All gene variants discussed can be found in Supplementary Table S1.
7.1.1. POMC
As discussed above, POMC has an integral role in leptin–melanocortin signalling, a neuroendocrine
pathway highly conserved across species. Raffan et al. [7] identified various canine POMC variants
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including a 14 bp deletion at position 17:19431807-19431821, present in Labrador retrievers and
flat-coated retrievers (FCRs) but absent from a wide variety of other breeds tested. The deletion was
shown to be a major modifier of weight, adiposity (measured as BCS on a 9-point scale), and appetite
(measured using a validated, owner-reported measure of eating behaviour [114]) in ≥210 Labrador
retrievers, with findings for weight and appetite replicated in ≥196 FCRs. Appropriate confounders
were accounted for by adjustment for age, sex, neuter status, and colour, thus association results can
be confirmed with high confidence. Notably, the mutation was more common in Labrador retrievers
working as assistance dogs compared to the pet population. For each additional allele carried by
either breed, there was an approximately 0.5 BCS/2 kg increase in adiposity/body mass, and a similar
incremental increase in food motivation.
The authors showed the POMC deletion results in altered production of β-MSH and β-endorphin,
two neuroactive peptides derived from POMC, and confirmed that canine MC4R receptors have similar
affinity for and response to α-MSH and β-MSH as the equivalent human pairings. Whilst the reduced
action of β-MSH on MC4R in the leptin–melanocortin signalling pathway is the most likely mechanism
resulting in this phenotype, β-endorphin may also be implicated.
Subsequent studies have confirmed the presence of this mutation [120,127,128]. In the British
Labrador retriever population, Davison et al. [127] found there was no association for the deletion
with occurrence of diabetes mellitus (DM) in the breed (a finding that is not surprising given that
obesity-associated insulin resistance is not clinically recognised as predisposing dogs to diabetes,
despite there being some epidemiological evidence that it may play a role population-wide).
The data had relevance to those studying human obesity biology, because canine POMC is highly
homologous to human POMC. The same cannot be said for rodents that lack a proteolytic cleavage
site in the pro-protein and so do not produce β-MSH. Since humans with mutations causing β-MSH
absence are very rare [129,130], the canine model in this case provided important insight into the role
of this particular peptide in energy homeostasis, as well as establishing a clear role for genetics in
governing obesity susceptibility in dogs.
7.1.2. MC4R
Canine MC4R gene polymorphisms have been identified in several studies, with some attempting
to analyse their effects on obesity-related phenotypes. MC4R is a suitable candidate gene due to
MC4R’s central position in the leptin–melanocortin pathway and given MC4R variants are among the
most common cause of monogenic human obesity. Humans with MC4R mutations are also modestly
taller than unaffected individuals of the same age and sex, or similarly obese unrelated subjects
without MC4R mutations [53,131]. The majority of the identified variants lack functional data for
characterisation of their consequences, but Yan et al. [132] reported that the missense variant c.637G>T
(p.Val213Phe, rs852614811) had no significant effect on cAMP-mediated signalling downstream of
the receptor.
Skorczyk et al. [133] conducted a study on canid MC4R, mapping and characterising it for the
first time. The study cohort incorporated 31 dogs of 19 breeds and 35 farmed red foxes (Vulpes vulpes).
They identified three polymorphic sites in the canine MC4R gene and four in the red fox. The three
canine MC4R polymorphisms identified were a non-synonymous variant (c.637G>T, p.Val213Phe,
rs852614811); a synonymous coding variant (c.777T>C, p.Ala259Ala, rs851987283); and a 3′UTR variant
(c.*33C>G, rs851539399). No association testing was conducted.
Van den Berg et al. [134] studied MC4R in 32 golden retrievers. They identified the same
polymorphic sites as Skorczyk et al. [133] (c.637G>T, p.Val213Phe, rs852614811; c.777T>C, p.Ala259Ala,
rs851987283; c.*33C>G, rs851539399), plus an additional synonymous coding variant (c.868C>T,
p.Leu290Leu, rs851062983). After linkage disequilibrium (LD) filtering, they performed an association
study for the three remaining polymorphisms (c.637G>T, c.777T>C, c.868C>T) in a larger cohort of
golden retrievers (n = 187). Several morphological measures were tested: weight, length, height, and
body index score (BIS), but not BCS. For the association, they appropriately corrected for sex, age, and
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polygenic effects. However, they do not mention any account for neuter status (a well-recognised risk
factor), and there was no measure of relatedness in the sample. No statistically significant association
was found for any of the phenotypes. Whilst this may be genuine, the study was underpowered to
find a small effect size, and these variants may warrant further investigation.
Zeng et al. [135] conducted an MC4R candidate gene study in beagles from a research colony. By
sequencing two beagle dogs, they identified the previously reported synonymous coding mutation
(c.777T>C, p.Ala259Ala, rs851987283) and a novel missense substitution (c.302C>A, p.Thr101Asn).
(Note that the way this mutation is referred to in the original paper and a subsequent review article is
somewhat confused. Zeng et al. [135] mis-name the mutations as C895T (for c.777T>C) and A420C (for
c.302C>A). The missense mutation (c.302C>A) results in an amino acid substitution from threonine
to asparagine (p.Thr101Asn = T101N), which can be clarified by figures within the paper. However,
they misname this as N101T. Mankowska et al. [136], in a subsequent review, note the mistake but
further misname it c.301A>C (p.Asn101Thr). The authors’ (unpublished) capillary sequencing data
means we can confirm the correct annotation as c.302C>A, p.Asn101Thr. Variant nomenclature
corrections can be found in Supplementary Table S1). In 120 beagles, c.302C>A was significantly
associated with body weight (p < 0.05). In contrast, c.777T>C was only significantly associated with
body weight in the heterozygous (but not homozygous) state and in bitches only. Whilst it is plausible
at least one of the single nucleotide polymorphisms (SNP) are associated with adiposity, there are
important limitations to the study. Specifically, weight does not equate to adiposity but could indicate
changes in height, length, or muscle mass. There was no adjustment for confounding factors such as
age, sex, or neuter status, and no assessment of whether the variants were in LD and therefore whether
these associations constitute independent signals.
Raffan et al. [7] sequenced the MC4R region in 33 Labrador retrievers of which 15 were obese and
18 were lean. Two novel MC4R variants were identified (c.989G>T, p.Ser330Ile; c.*227C>T) plus three
previously reported variants (c.637G>T, p.Val213Phe, rs852614811; c.*33C>G, rs851539399; c.777T>C,
p.Ala259Ala, rs851987283). None were distributed differently between the small lean and obese groups,
and the variants were not pursued further. This group also sequenced AGRP in this cohort, another
valid candidate gene which codes for agouti-related protein—a neuropeptide known to modulate food
intake in the ARC [137]. No AGRP variants were identified.
Mankowska et al. [136] investigated MC4R variants in 270 dogs of four breeds in which they
identified six known polymorphic sites (c.637G>T, p.Val213Phe, rs852614811; c.777T>C, p.Ala259Ala,
rs851987283; c.868C>T, p.Leu290Leu, rs851062983; c.*33C>G, rs851539399; c.*227C>T; and c.-435T>C,
rs852471376). Of the 270 dogs, they had full phenotypic data for 164. They concluded that none
of the identified variants displayed differential association with BCS (5-point scale) or body weight.
The study population was dominated by Labrador retrievers (n = 187) and no potential confounding
factors were accounted for.
7.1.3. FTO
The top association signal on most human GWAS for BMI, FTO, is of debatable merit as a candidate
gene for canine obesity, due to the controversy as to whether FTO itself or neighbouring genes are
the true effector pathway causing the association signal (see above). Grzes et al. [138] investigated
FTO SNPs in four Canidae species including the dog. In 39 dogs of 14 breeds, sequencing identified
six polymorphic sites in FTO: one missense variant (c.23C>T, p.Thr8Met, rs852870212 described as
“23 C/T, Thr1Met”), two intronic variants, and three 3′ flanking variants. Presence of the missense
mutation differed by dog breed, but the small number of dogs genotyped meant association tests
were (appropriately) not performed. However, of seven FTO polymorphisms in the red fox, one (a
5′ flanking region variant) was tested for association with body weight and pelt weight (which the
authors report is affected by subcutaneous fat mass) in a larger cohort of 390 red foxes. No significant
association was identified.
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Grzemski et al. [139] used targeted next generation sequencing (NGS) in 32 Labrador retrievers in a
region incorporating FTO and IRX3. Several polymorphisms were identified and tested for association
with BCS (5-point scale) in a larger Labrador retriever cohort (n = 165), suitably adjusted for sex, age,
and multiple testing. No association was found. The authors reported 56% nucleotide identity between
human and canine FTO and 72% for IRX3. Additionally, they compared methylation status of CpG
islands between lean and obese dogs in a smaller cohort (n = 28)—no differences were found.
7.1.4. MC3R
Skorczyk et al. [140] conducted a candidate gene study on the gene encoding melanocortin receptor
3 (MC3R). The MC3R gene is a reasonable candidate, although it is notable that rodent and human
phenotypes associated with MC3R variants are more subtle than for the related MC4R, with MC3R
most likely affecting the maintenance of body mass within the homeostatically controlled upper and
lower limits [141–144].
The study cohort used by Skorczyk et al. [140] consists of four canid species: 31 dogs of 19 breeds,
35 red foxes, 30 arctic foxes (Vulpes lagopus/Aloplex lagopus), and 30 Chinese raccoon dogs (Nyctereutes
procyonoides procyonoides). Multiple polymorphisms were found in MC3R in three of the species;
no variants were identified in MC3R of the arctic fox. Two polymorphic sites were identified in the dog:
short tandem repeat (STR) in 5’ flanking region (c.-90delT, rs853092001) and a synonymous substitution
(c.142C>T, p.Leu48Leu, rs8916554). Association analysis for MC3R variants was then performed in
cohort of 376 male red foxes. Two SNPs were in LD and both were associated with a small, statistically
significant increase in body mass. There was limited information provided on potential environmental
confounders and population stratification, with no apparent adjustment. It therefore cannot be ruled
out that any associations observed may be as a result of these factors.
7.1.5. INSIG2
Insulin-induced gene 2 protein (INSIG2) has a role in lipid metabolism and has been linked in
human GWAS studies to various measures of circulating blood lipids. Its coding gene (INSIG2) has been
implicated in human GWAS for BMI [145], but that association has not been reliably replicable [146],
so its validity as a candidate obesity gene is somewhat limited. Grzes et al. [138] analysed polymorphic
sites in INSIG2 in four Canidae species including the dog. In 32 dogs of 14 breeds, seven polymorphic
sites were identified: two 5′ UTR variants referred to as 5′ flanking region variants, (c.-90G>A
(referred to as–91 G/A), rs852813691; c.-1C>T, rs852335828), one missense variant (c.40C>A, p.Arg14Ser,
rs850773724), and four intronic variants. No association test was conducted in dogs, but one intronic
SNP identified in the red fox was significantly associated with pelt weight in 390 red foxes. Skin weight
may be influenced by subcutaneous fat mass, but this is not a valid measure of adiposity and such
findings in the red fox may not be translatable to dogs.
7.1.6. GPR120/FFAR4
G-protein coupled receptor 120 (GPR120), also known as free fatty acid receptor 4 (FFA4/FFAR4),
functions as a receptor for unsaturated long-chain free fatty acids. The gene encoding this protein is
known as GPR120/FFA4/FFAR4 [147,148], and coding mutations in the gene have been associated with
human obesity [149]. The following variants are described based on alignment to the canine FFAR4
gene. Miyabe et al. [150] found nine FFAR4 polymorphisms in a cohort of 141 dogs of 21 breeds: five
synonymous substitutions (c.252C>G, p.Ala84Ala, rs852631320; c.282C>G, p.Pro94Pro (referred to as
p.Asp94Asp), rs851850900; c.702A>G, p.Thr234Thr; c.726G>A, p.Thr242Thr; c.984T>C, p.Asn328Asn,
rs852472019) and four non-synonymous substitutions (c.287T>G, p.Leu96Arg; c.307G>A, p.Ala103Thr;
c.446G>C, p.Gly149Ala; c.595A>C, p.Thr199Pro, rs853030954 (referred to as c.595C>A, p.Thr199Pro)).
SNPs were tested for association with BCS, the frequency of c.595A>C (referred to as c.595C>A) was
significantly higher in dogs with a higher BCS. However, several confounding factors are unaccounted
for and the study failed to correct for population stratification. Therefore, such identified associations
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may have been due to confounders or, given the unequally represented multi breed cohort, due to
unaccounted-for population stratification.
7.1.7. PPARs
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins
that function as transcription factors and have roles in the regulation of cellular differentiation,
development, and metabolism [151,152]. Nishii et al. [153] sequenced the genes encoding PPARβ
and PPARγ (PPARB and PPARG) in two dogs and observed tissue-specific expression of various
PPARs. They also investigated the presence of polymorphic sites in PPARG and identified a single
polymorphism. No association test with phenotype was conducted. Since a relatively small canine
cohort were genotyped, it is possible that other PPARB polymorphisms were missed.
7.1.8. Adipokines
Adipose tissue communicates with the rest of the body in part by release of a range of molecular
signals known as adipokines. Adipokines include leptin, pro-inflammatory molecules such as TNFα
and IL6, and the much-debated resistin, the latter three of which were investigated in dogs by
Mankowska et al. [154]. The choice of these genes is a little surprising in that, although there is
evidence that each has a role in the development of insulin resistance secondary to obesity, there is
little evidence that variants promoting inflammation are causal in obesity [155] and considerable
evidence to the contrary (https://www.ebi.ac.uk/gwas/) [156]. Nevertheless, in 77 dogs of 17 breeds,
Mankowska et al. identified multiple variants, including 13 in TNF, four in IL6, and eight in
RETN. Three of these variants were missense substitutions: one in TNF (c.548A>T, p.Glu183Val)
and two in RETN (c.19C>T, p.Leu7Phe, rs852470997; c.236C>G, p.Ser79Cys, rs851766760—referred
to in the paper as a synonymous coding variant). The five most common variants (TNF: c.-40A>C,
rs22216187; c.233+14G>A; IL6: c.309+215T>C; RETN: c.194-69T>A, rs853182485; c.75G>A, p.Glu25Glu,
rs852185407) were genotyped in 260 dogs and tested for association with BCS, using breed-specific
sub-groups to do the association analysis, including an “others” category for the poorly represented
breeds. No association was found for the IL6 and RETN variants with BCS in any breed group. The two
TNF SNPs (c.-40A>C and c.233+14G>A) were significantly associated with body condition in Labrador
retrievers but not in any other breed group. Whilst those associations may be meaningful, the failure to
include recognised risk factors such as age, sex, and neuter status or to detect or correct for population
stratification in the sample could have affected these results.
8. Feline Obesity and Associated Disease
Estimates suggest 12–63% of pet cats are overweight or obese [2,157–162]. Feline obesity is
associated with multiple comorbidities, most notably DM and hepatic lipidosis [12,158,163–167].
This arguably makes human and feline obesity comorbidities closer compared to dogs [168,169].
However, human comorbidities such as hypertension and atherosclerosis are not commonly observed
in obese cats [107,170,171].
Obesity’s relationship to DM in cats is well characterised with evidence suggesting a similar
pathophysiology to human T2D [107,171–173] in which obesity leads to insulin resistance and ultimately
β-cell dysfunction and diabetes [166,173–177]. Cats are therefore considered a suitable animal model
for study of obesity associated T2D, with translational significance to humans. In contrast, whilst
obesity is a well-recognised risk factor for feline hepatic lipidosis, the pathophysiological link between
the two is less well characterised and subject to some debate [176,178,179].
8.1. Evidence for the Role of Genetics in Feline Obesity and Related Disease
Multiple studies suggest breed as a risk factor of feline obesity, with certain breeds displaying
predisposition to becoming overweight/obese [12,180–182]. Although breed-specific obesity risk differs
by study, domestic shorthaired cats (DSH) are consistently found to be at high risk, whilst longhaired
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breeds are generally at lower risk. Persian cats also have low obesity risk in most studies [12,181,182],
but one study found them to be at high risk [180]. Together, these data suggest obesity may be at least
in part a heritable trait in cats.
Notably, pet cats are made up of a majority of mixed breed cats (commonly referred to as DSH
and domestic long-haired (DLH) breeds but are most commonly outbred and relatively genetically
diverse) and a minority of pedigree cats, in which genetic architecture is reminiscent of dogs, with low
within-breed diversity and evidence of population bottlenecks and genetic selection [183,184].
Until recently, genetic studies in cats have been stymied by the absence of a well-annotated,
complete feline genome and lack of a commercial feline SNP genotyping array. Consequently, there
are fewer genetic studies reported in cats overall, and none of the common forms of feline obesity.
However, one group has reported candidate gene studies for feline DM [185], a related trait and one
that is likely to be subject to similar genetic influences (including overlap with obesity predisposition)
as described above for humans.
8.2. Familial Obesity in a Feline Colony
In a population of well-characterised, related research cats, a familial form of obesity has been
reported [186]. Some cats displayed a clear predisposition to obesity, and segregation analysis suggested
a single major gene was likely responsible. The report is more akin to human monogenic obesity or
mutations of large effect against a variably obesogenic polygenic background.
A subsequent study found that the cats predisposed to being obese had a lower energy requirement
and higher food intake than cats that did not tend to gain weight [187]. However, the energy requirement
measurements were (for the obesity-prone group) performed not long after a period of restricted feeding
and weight loss, interventions well recognised to cause reduced energy expenditure irrespective of
baseline status [188]. In a subsequent generation of the same cohort, food intake and energy expenditure
were investigated [189], and obesity-prone cats had higher food intake early in life but not lower
energy expenditure.
In the same feline cohort, Keller et al. [190] investigated metabolic responses to different diets in
cats predisposed to obesity vs. lean cats. No difference in metabolic response was found between the
two groups. Additionally, in conference proceedings [191] the same group report attempts to map
obesity genes were made and identified plausible candidate genes. Further comment is not possible
given the scant information reported.
8.3. Genetics of Diabetes Mellitus in Pet Cats
Forcada et al. [185] investigated whether MC4R polymorphisms were associated with diabetes in
DSH and Burmese cats. For each of a non-diabetic control group and a diabetic case group, there were
60 lean and 60 overweight cats, making 240 in total. The authors report that one MC4R polymorphism
(c.92 C>T, p.Leu31Pro, rs783632116) was significantly more common in obese diabetic cats than obese
non-diabetic cats, a finding not replicated in lean cats. Heterozygous and homozygous carriers in the
non-diabetic subgroup were merged (assuming a dominant mode of inheritance). The authors do not
report comparison of allele frequencies between lean and overweight cats (irrespective of DM status).
The authors speculate that this variant may act independently of an effect on body weight, but
these reviewers suggest that to be a bold statement given the limitations of the data presented and the
weight of evidence from other species about the role of MC4R in controlling food intake and obesity
predisposition. For example, although MC4R is significantly associated with T2D in human GWAS,
that association disappears when the analysis model corrects for BMI [192,193]. Consequently, it seems
equally or more plausible that the association reported may in fact be a result of vertical pleiotropy
rather than a direct effect.
The same group in conference abstracts report the results of a GWAS for feline DM in a cohort
of 581 DSH cats [194,195], later adding Burmese cats [196]. However, the data are not reported in
sufficient detail to reiterate here.
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9. Obesity and Related Metabolic Disease in Horses
As in other companion animal species, equine obesity is common with an estimated 20–70%
of horses overweight/obese [11,197–200]. This is a significant clinical problem, because obesity is
a risk factor for the development of laminitis, a common, crippling disorder of the equine hoof.
That association is thought to be mediated predominantly via a collection of risk factors known as
equine metabolic syndrome (EMS). EMS was first described in 2002 [201], and the pathophysiological
links between obesity and laminitis have been extensively studied since, although it is acknowledged
that the current working understanding requires refinement [202].
EMS is defined by the presence of insulin dysregulation, characterised by clinical features including
hyperinsulinaemia (either at baseline or in response to glucose challenge), hyperglycaemia, and/or
evidence of peripheral insulin resistance [202]. Insulin resistance is commonly present in EMS, although
there has been some debate as to whether that is always true and if alternative routes by which insulin
dysregulation may develop exist [203]. Notably, although obesity and EMS are common, it is rare for
horses and ponies to become diabetic [202].
Not all overweight equines develop EMS, nor does EMS always cause laminitis. Similarly, not all
horses that have clinical features of EMS are overweight. Those paradoxes exist between individuals
and across breeds, with some breeds apparently particularly prone to developing laminitis despite only
moderate weight gain [198]. This is reminiscent of the situation described above in humans, whereby
there is variability between individuals and ethnic groups concerning whether, and at what point,
obesity-associated complications occur. It is clear, therefore, that a better understanding of equine
obesity and its related conditions is required.
9.1. Genetics Influence Equine Obesity, EMS, and Laminitis
Evidence that genetics influence the development of equine obesity come from recognition
that breed and “type” are clear risk factors with ponies at highest risk, followed by cob type
breeds [11,204–208]. In Pura Raza Español horses, the heritability of BCS was found to be 14–24% [209].
Importantly, a within-breed study can only estimate the variance due to genetic variation within that
(homogeneous) breed, so this heritability figure should not be generalised to the species as a whole.
To date, there are no reports of GWAS or candidate gene studies in equine obesity.
The genetics of EMS have been more intensively interrogated. Breed is a well-recognised risk
factor and breeds largely overlap with breeds at high obesity risk, unsurprising given the association
between the conditions [202]. A similar variability between breeds has been demonstrated for insulin
sensitivity and related biochemical parameters [210–213]. A recent study used genome-wide SNP data
to estimate heritability of several traits known to be perturbed by EMS (glucose, insulin, measures
of insulin sensitivity, and dyslipidaemia) and found they were moderately to highly heritable [214].
Again, such within-breed comparisons are valuable but are likely to underestimate the true heritability
in the equine population.
Genetic studies of laminitis are worthy of report, given the common co-segregation of obesity,
EMS, and laminitis. In an early study of crossbreed ponies, the authors concluded laminitis was
a dominant trait in the pedigree with variable penetrance due to sex, age, and epigenetic-related
variables [215]. Subsequent GWAS are mentioned below.
9.2. GWAS for EMS and Related Traits
Lewis et al. [216] performed a GWAS for laminitis and related traits in a population of 64 Arabian
horses. A locus on chromosome 14 was associated with laminitis and insulin concentration. In a second
cohort of 50 horses of the same breed, the identical phenotypes were not available, but the same region
was associated with BCS and an alternative measure of insulin resistance. The closest gene was the
poorly characterised FAM174A, which the authors sequenced. They found two closely linked variants,
present in multiple breeds. The authors suggested an 11-guanine polymorphism near FAM174A
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might have potential as a predictive test for horses at risk of obesity/EMS/laminitis. Subsequently,
an Australian group found no association with metabolic traits for that marker in 20 (non-Arabian)
ponies [217]. Similarly, a larger study in multiple breeds, including Arabians, failed to replicate the
BCS, laminitis, or insulin resistance associations, although assuming a dominant model did identify a
significant association with the adipokine adiponectin [218].
Selective breeding can lead to enrichment of alleles within a breed, which are scarce in the wider
population, meaning it is plausible that a genetic variant may exist in Arabians at this locus, genetically
linked to the 11-guanine allele but which has yet to be identified. Thus, a real finding in Arabians might
not be replicated in other breeds. However, replication in a larger, independent cohort of Arabians
would be advisable. There is no evidence that this allele would be a suitable genetic test for obesity,
EMS, or laminitis predisposition in other breeds.
Norton et al. [219] recently performed a GWAS focussed on EMS in a larger equine cohort (n = 550)
representing two high-risk breeds (Welsh ponies and Morgan horses). By collecting rich metabolic
data, they were able to test for association with multiple “endophenotypes”, more precise biochemical
markers of insulin-related traits. Using endophenotypes may be more informative than performing a
GWAS for a “convergent” phenotype such as laminitis, which can represent the clinical endpoint of
multiple pathophysiological processes. The group appropriately adjusted for relevant confounding
factors and for population stratification although not for BCS, meaning the results may identify loci
associated with obesity rather than EMS per se. Hundreds of loci were identified across the multiple
genome scans and the authors prioritised those which appeared to affect more than one breed.
The authors expressed surprise that there was not more overlap between breeds. That may be
because major genetic determinants may be private to individual breeds, but it is perhaps more likely
that the study was underpowered to find variants of small effect, or which were rare or invariate
in one population. Protein coding genes in prioritised regions were enriched for involvement in
pathways of inflammation, glucose metabolism, and lipid metabolism, all plausible as contributing to
EMS pathology.
A final equine study considered the gene HMGA2, which had previously been identified as
associated with short stature in pony breeds. In humans, short stature is a risk factor for insulin
resistance. Concordantly, a study found pony breeds (which are smaller than horses) are more
likely to get EMS [220]. The authors hypothesised a causal link between HMGA2 and increased EMS
susceptibility in ponies. They found a strong association with height in 264 Welsh ponies and a lesser
association with several metabolic traits, which they reported as a pleiotropic effect.
10. From Humans to Animals and Back Again
10.1. Lessons for Animal Genetics
This review has summarised the wealth of research into the genetics of human obesity and its
related metabolic perturbations, and the relative paucity of efforts to date in dogs, cats, and horses.
Consequently, those studying veterinary species have much to learn from human geneticists and those
studying laboratory animal models. By familiarising ourselves with those fields, there is much scope
to fast-track animal studies to provide maximum insight into animal disease.
In particular, we note how careful delineation of clinical phenotypes has led to both genetic
diagnoses and mechanistic insight in human patients, such as with familial partial lipodystrophy.
Historically, such lean patients presenting with metabolic syndrome or T2D were considered inexplicable
outliers. By recognising groups with shared clinical features, lipodystrophy has been recognised,
patient care has improved, and we have a matured understanding of how healthy fat depots are
essential to metabolic health [98]. Might similar clinical groupings exist, unrecognised, as underlying
atypical presentations of EMS or determining why only some overweight cats become diabetic?
Human genetic epidemiological studies have, for some time, attempted to address the issue of
cause and consequence between obesity and related pathologies. Performing GWAS not only for
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endpoints such as T2D or NAFLD, but also for those phenotypes corrected for BMI was a start in
teasing out causal relationships between them, a process that has been improved with the advent of
Mendelian randomisation [95]. Such approaches operate best at scale, which may limit their application
in veterinary studies. Even so, an acute awareness that multiple routes can converge on a single
phenotype (e.g., obesity, adipose dysfunction, and insulin signalling impairment converge to produce
signs of metabolic syndrome) should inform our design and interpretation of veterinary GWAS.
Finally, human genetics also provides a lead in how to maximise the benefit of genetic studies.
One notable contrast is that results of human genetic studies are rarely left “hanging”—mapped loci
are further investigated, mouse models made to test the function of unknown genes, patients with
specific genetic diagnoses are further studied, and precision treatments developed. This reflects a
more established, larger, and better-funded research environment but provides a model for veterinary
researchers to emulate.
Genetic findings have informed best practice to flag patients with uncommon presentations
of common disease who may benefit from precision treatments [98,221]. In common, polygenic
human disease, PRS are being used to counsel human patients about disease risk [80] and to stratify
patients in research studies to understand better variable penetrance of variants of large effect [57].
In companion animals, there is a genetic test available for the retriever POMC mutation that can warn
owners they have a dog at high risk of obesity and prompt them to effectively institute appropriate
preventative measures [7], but other genetic findings in the field of obesity have yet to reach the
veterinary clinic. Might we in future years detect cats with insulin signalling defects as candidates
for insulin sensitising drugs in the pre-diabetic stage? Or might genetic profiling identify ponies at
highest risk of laminitis? If so, genetic testing might prove a valuable clinical tool although one to be
used only after robust validation of their utility in populations (e.g., breeds) different to that in which
they were initially proposed.
10.2. Lessons from Animal Genetics
Fortunately, the flow of information between species need not be along a one-way street. Genetic
studies of animal disease have already been informative to human research [7,222,223], and there is
much potential to discover more. As genomic tools and better-annotated genomes become available,
veterinary studies will be better able to provide insight into not just disease-associated loci but particular
genes, mutations, and mechanisms too. That will clearly be a benefit to the species studied but also has
the potential to benefit human health.
The current quality of genome builds and genomic tools available for companion animal studies
vary by species. In dogs, the third-generation genome build (CanFam 3.1) has been available since
2014 [224], based on data from a Boxer dog, Tasha. Sequencing efforts integrating data from long read
technologies produced genome sequences from a Great Dane (UMICH_Zoey_3.1, GCA_005444595.1,
PacBio RSII) [225] and a basenji, (Basenji_breed-1.1, GCA_004886185.2, Sequel), meaning there are now
three potential reference sequences available in the species. Canine geneticists were also the first to
drive production of commercial companion animal genotyping arrays, with the earliest containing 49k
SNP markers [226], later increasing to 173k, 220k (CanineHD BeadChip, Illumina, San Diego, CA, USA),
and 710k densities (CanineHD Array, Thermofisher, Waltham, MA, USA). Today, there are available
arrays that cover >1 million genetic markers (Canine Genotyping Array, Thermofisher, Waltham, MA,
USA), a subset of which were selected for use on the 460k/670k arrays (Canine Genotyping Array
A/B, Thermofisher, Waltham, MA, USA). Additionally, high quality imputation from a lower to higher
density SNP array level and to genome sequencing density has been successful in dogs [227,228].
In cats, the newest genome build (Felis_catus_9.0) was made available in 2017 [184], and one
relatively low-density genotyping array of 63k SNP markers exists [229] but is not commercially
available. No use of imputation software in cats has been reported. In horses, the most recent genome
build EquCab3.0 has been available since 2018 [230], and the first equine array was reported in 2014 at
a density of 54k (Equine BeadChip, Illumina, San Diego, CA, USA) [231]. Nowadays, two more SNP
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arrays exist, both of which are commercially available, with marker densities of 65k (Equine BeadChip,
Illumina, San Diego, CA, USA) and 670k (MNEc670K, Affymetrix, Santa Clara, CA, USA) [232].
Notably, a test equine array containing 2 million markers (MNEc2M) was created to inform the creation
of MNEc670K and used successfully for imputation [232,233]. Imputation has also been performed in
an equine population, from 54/65k density up to 670k [234].
Companion animal models of disease have the potential to “add value” to understanding broader
biology for many reasons. Our animal companions share our homes and environments, spontaneously
develop diseases similar to human conditions, for which they are often diagnosed and treated similarly
but over a shorter time course. In some cases, disease processes that occur commonly in companion
animals may be hard to study in humans. For instance, the retriever POMC mutation occurs in
approximately 25% of Labrador retrievers, but the equivalent human mutations are very rare. The same
molecule, β-MSH, is absent in rodents. Hence, in this situation, dogs provide an excellent animal
model to shed light on a previously hard-to-illuminate area of human biology [7].
Similarly, cats are arguably more suitable than traditional animal models for the study of obesity
associated T2D. Diabetes in cats bares closer resemblance to human T2D than that of the rodent model;
it occurs naturally in cats, whereas T2D research in rodents is most often an induced disease state [235].
This means using the feline model of diabetes offers benefits for improved understanding of human
T2D development, particularly for polygenic models [236,237].
Notably, there are advantages to studying such inbred populations, particularly dogs. Recent
population bottlenecks at breed formation mean dogs have a very different genetic architecture to
humans that makes complex trait mapping uniquely tractable in the species [238]. This means complex
traits can be mapped in a breed with fewer individuals and fewer markers than in human populations.
Dogs are therefore a compelling model for studying human metabolic disease [77,239–241]. Although,
trait mapping in such inbred species means mapping to much larger loci than in humans [242,243],
making causative variant identification within an associated locus more difficult.
Although cats do not display the same high level of LD as dogs, they have also been selectively
bred and are proposed as potentially valuable models of human hereditary disease [183,244,245].
Horse genomes display lower levels of LD than both dogs and cats [183], but breed structure means
there is potential for disease alleles being enriched and relatively easily studied within a discrete,
definable population, meaning they too have potential to be valuable models of human disease [246].
11. Conclusions
The obesity epidemic is a major health concern in both human and companion animals, and there
is a lot more to be discovered regarding the molecular basis of obesity and associated metabolic
conditions. Despite clear evidence that obesity and related traits are highly heritable in companion
animals, there are only limited studies to date investigating which genes are responsible and how
they exert their effect. As this field matures, it promises tangible benefits for animal populations and,
where considered as non-traditional animal models of obesity, has the potential to offer translational
benefits too.
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164. Kocabağlı, N.; Kutay, H.C.; Dokuzeylül, B.; Süer, İ.N.E.; Apt, M. The Analysis of Computer Data regarding
Obesity and Associated Diseases in Cats Examined at Private Veterinary Practices. Acta Sci. Vet. 2017, 45, 5.
[CrossRef]
165. Center, S.A. Feline hepatic lipidosis. Vet. Clin. N. Am. Small Anim. Pract. 2005, 35, 225–269. [CrossRef]
166. Hoenig, M.; Thomaseth, K.; Waldron, M.; Ferguson, D.C. Insulin sensitivity, fat distribution, and adipocytokine
response to different diets in lean and obese cats before and after weight loss. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 2007, 292, R227–R234. [CrossRef]
167. Raffan, E. The big problem: Battling companion animal obesity. Vet. Rec. 2013, 173, 287–291. [CrossRef]
[PubMed]
168. Kooistra, H.S.; Galac, S.; Buijtels, J.J.; Meij, B.P. Endocrine diseases in animals. Horm. Res. 2009, 71 (Suppl. S1),
S144–S147. [CrossRef] [PubMed]
169. Van de Velde, H.; Janssens, G.P.; de Rooster, H.; Polis, I.; Peters, I.; Ducatelle, R.; Nguyen, P.; Buyse, J.;
Rochus, K.; Xu, J.; et al. The cat as a model for human obesity: Insights into depot-specific inflammation
associated with feline obesity. Br. J. Nutr. 2013, 110, 1326–1335. [CrossRef] [PubMed]
170. Jordan, E.; Kley, S.; Le, N.A.; Waldron, M.; Hoenig, M. Dyslipidemia in obese cats. Domest. Anim. Endocrinol.
2008, 35, 290–299. [CrossRef] [PubMed]
171. Hoenig, M. The cat as a model for human obesity and diabetes. J. Diabetes Sci. Technol. 2012, 6, 525–533.
[CrossRef] [PubMed]
172. Rand, J.S.; Fleeman, L.M.; Farrow, H.A.; Appleton, D.J.; Lederer, R. Canine and feline diabetes mellitus:
Nature or nurture? J. Nutr. 2004, 134, 2072S–2080S. [CrossRef]
173. Osto, M.; Lutz, T.A. Translational value of animal models of obesity-Focus on dogs and cats. Eur. J. Pharmacol.
2015, 759, 240–252. [CrossRef]
174. Osto, M.; Zini, E.; Reusch, C.E.; Lutz, T.A. Diabetes from humans to cats. Gen. Comp. Endocrinol. 2013,
182, 48–53. [CrossRef]
175. Zini, E.; Osto, M.; Franchini, M.; Guscetti, F.; Donath, M.Y.; Perren, A.; Heller, R.S.; Linscheid, P.; Bouwman, M.;
Ackermann, M.; et al. Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell
loss in the domestic cat. Diabetologia 2009, 52, 336–346. [CrossRef]
Genes 2020, 11, 1378 26 of 29
176. Clark, M.; Hoenig, M. Metabolic Effects of Obesity and Its Interaction with Endocrine Diseases. Vet. Clin. N.
Am. Small Anim. Pract. 2016, 46, 797–815. [CrossRef]
177. Häring, T.; Haase, B.; Zini, E.; Hartnack, S.; Uebelhart, D.; Gaudenz, D.; Wichert, B.A. Overweight and
impaired insulin sensitivity present in growing cats. J. Anim. Physiol. Anim. Nutr. (Berl.) 2013, 97, 813–819.
[CrossRef] [PubMed]
178. Center, S.A.; Crawford, M.A.; Guida, L.; Erb, H.N.; King, J. A retrospective study of 77 cats with severe
hepatic lipidosis: 1975-1990. J. Vet. Intern. Med. 1993, 7, 349–359. [CrossRef] [PubMed]
179. Verbrugghe, A.; Bakovic, M. Peculiarities of one-carbon metabolism in the strict carnivorous cat and the role
in feline hepatic lipidosis. Nutrients 2013, 5, 2811–2835. [CrossRef] [PubMed]
180. Corbee, R.J. Obesity in show cats. J. Anim. Physiol. Anim. Nutr. (Berl.) 2014, 98, 1075–1080. [CrossRef]
181. Ohlund, M.; Palmgren, M.; Holst, B.S. Overweight in adult cats: A cross-sectional study. Acta Vet. Scand.
2018, 60, 5. [CrossRef]
182. Colliard, L.; Paragon, B.M.; Lemuet, B.; Benet, J.J.; Blanchard, G. Prevalence and risk factors of obesity in an
urban population of healthy cats. J. Feline Med. Surg. 2009, 11, 135–140. [CrossRef]
183. Alhaddad, H.; Khan, R.; Grahn, R.A.; Gandolfi, B.; Mullikin, J.C.; Cole, S.A.; Gruffydd-Jones, T.J.; Haggstrom, J.;
Lohi, H.; Longeri, M.; et al. Extent of linkage disequilibrium in the domestic cat, Felis silvestris catus, and its
breeds. PLoS ONE 2013, 8, e53537. [CrossRef]
184. Zhang, W.; Schoenebeck, J.J. The ninth life of the cat reference genome, Felis_catus. PLoS Genet. 2020,
16, e1009045. [CrossRef]
185. Forcada, Y.; Holder, A.; Church, D.B.; Catchpole, B. A polymorphism in the melanocortin 4 receptor gene
(MC4R:c.92C>T) is associated with diabetes mellitus in overweight domestic shorthaired cats. J. Vet. Intern.
Med. 2014, 28, 458–464. [CrossRef]
186. Häring, T.; Wichert, B.; Dolf, G.; Haase, B. Segregation analysis of overweight body condition in an
experimental cat population. J. Hered. 2011, 102 (Suppl. S1), S28–S31.
187. Wichert, B.; Trossen, J.; Uebelhart, D.; Wanner, M.; Hartnack, S. Energy requirement and food intake behaviour
in young adult intact male cats with and without predisposition to overweight. Sci. World J. 2012, 2012,
509854. [CrossRef] [PubMed]
188. Speakman, J.R.; Levitsky, D.A.; Allison, D.B.; Bray, M.S.; de Castro, J.M.; Clegg, D.J.; Clapham, J.C.;
Dulloo, A.G.; Gruer, L.; Haw, S.; et al. Set points, settling points and some alternative models: Theoretical
options to understand how genes and environments combine to regulate body adiposity. Dis. Model. Mech.
2011, 4, 733–745. [CrossRef] [PubMed]
189. Ghielmetti, V.; Wichert, B.; Ruegg, S.; Frey, D.; Liesegang, A. Food intake and energy expenditure in growing
cats with and without a predisposition to overweight. J. Anim. Physiol. Anim. Nutr. (Berl.) 2018, 102,
1401–1410. [CrossRef]
190. Keller, C.; Liesegang, A.; Frey, D.; Wichert, B. Metabolic response to three different diets in lean cats and cats
predisposed to overweight. BMC Vet. Res. 2017, 13, 184. [CrossRef] [PubMed]
191. Wichert, B.; Häring, T.; Dolf, G.; Trossen, J.; Haase, B.; Szymecko, R.; Iben, C.; Burlikowska, K.; Sitkowska, B.
Feline Bodyweight: Genetic Aspects of Food Intake. In Proceedings of the 16th Congress of the European
Society of Veterinary and Comparative Nutrition, Bydgoszcz, Poland, 13–15 September 2012; European
Society of Veterinary & Comparative Nutrition: Zürich, Switzerland, 2012; Volume 31.
192. Zobel, D.P.; Andreasen, C.H.; Grarup, N.; Eiberg, H.; Sorensen, T.I.; Sandbaek, A.; Lauritzen, T.;
Borch-Johnsen, K.; Jorgensen, T.; Pedersen, O.; et al. Variants near MC4R are associated with obesity
and influence obesity-related quantitative traits in a population of middle-aged people: Studies of 14,940
Danes. Diabetes 2009, 58, 757–764. [CrossRef]
193. Cauchi, S.; Stutzmann, F.; Cavalcanti-Proenca, C.; Durand, E.; Pouta, A.; Hartikainen, A.L.; Marre, M.; Vol, S.;
Tammelin, T.; Laitinen, J.; et al. Combined effects of MC4R and FTO common genetic variants on obesity in
European general populations. J. Mol. Med. (Berl.) 2009, 87, 537–546. [CrossRef]
194. Forcada, Y.; Boursnell, M.; Catchpole, B.; Church, D.B. A Genome-Wide Association Study Identifies Novel
Candidate Genes for Susceptibility to Diabetes Mellitus in DSH Cats. In Proceedings of the Conference
Proceedings: 25th ECVIM-CA Congress, Lisbon, Portugal, 10–12 September 2015.
195. Forcada, Y.; Boursnell, M.; Catchpole, B.; Church, D.B. A Genome-Wide Association Study Identifies Novel
Candidate Genes for the Susceptibility to Diabetes Mellitus in DSH Cats. In Proceedings of the Conference
Proceedings: ACVIM, Am College Vet Internal Med Forum, Denver, CO, USA, 9–11 June 2016.
Genes 2020, 11, 1378 27 of 29
196. Hazuchova, H.; Wallace, M.; Church, D.B.; Catchpole, B.; Forcada, Y. Analysis of GWAS Data in Domestic
Shorthair and Burmese Cats Identifies Diabetes-associated Loci Near the DPP9 and Within the DPP10 Gene.
In Proceedings of the Conference Proceedings: 29th ECVIM-CA Congress, European Coll Vet Int Med,
Milano, Italy, 19–21 September 2019.
197. Rendle, D.; McGregor-Argo, C.; Bowen, M.; Carslake, H.; German, A.; Harris, P.; Knowles, E.; Menzies-Gow, N.;
Morgan, R. Equine obesity: Current perspectives. UK Vet. Equine 2018, 2, 1–19. [CrossRef]
198. McCue, M.E.; Geor, R.J.; Schultz, N. Equine metabolic syndrome: A complex disease influenced by genetics
and the environment. J. Equine Vet. Sci. 2015, 35, 367–375. [CrossRef]
199. Thatcher, C.D.; Pleasant, R.S.; Geor, R.J.; Elvinger, F. Prevalence of overconditioning in mature horses in
southwest Virginia during the summer. J. Vet. Intern. Med. 2012, 26, 1413–1418. [CrossRef]
200. Stephenson, H.M.; Green, M.J.; Freeman, S.L. Prevalence of obesity in a population of horses in the UK.
Vet. Rec. 2011, 168, 131. [CrossRef]
201. Johnson, P.J. The equine metabolic syndrome peripheral Cushing’s syndrome. Vet. Clin. N. Am. Equine Pract.
2002, 18, 271–293. [CrossRef]
202. Durham, A.E.; Frank, N.; McGowan, C.M.; Menzies-Gow, N.J.; Roelfsema, E.; Vervuert, I.; Feige, K.; Fey, K.
ECEIM consensus statement on equine metabolic syndrome. J. Vet. Intern. Med. 2019, 33, 335–349. [CrossRef]
[PubMed]
203. de Laat, M.A.; McGree, J.M.; Sillence, M.N. Equine hyperinsulinemia: Investigation of the enteroinsular axis
during insulin dysregulation. Am. J. Physiol. Endocrinol. Metab. 2016, 310, E61–E72. [CrossRef] [PubMed]
204. Potter, S.J.; Bamford, N.J.; Harris, P.A.; Bailey, S.R. Prevalence of obesity and owners’ perceptions of body
condition in pleasure horses and ponies in south-eastern Australia. Aust. Vet. J. 2016, 94, 427–432. [CrossRef]
[PubMed]
205. Giles, S.L.; Rands, S.A.; Nicol, C.J.; Harris, P.A. Obesity prevalence and associated risk factors in outdoor
living domestic horses and ponies. PeerJ 2014, 2, e299. [CrossRef]
206. Morrison, P.K.; Harris, P.A.; Maltin, C.A.; Grove-White, D.; Barfoot, C.F.; Argo, C.M. Perceptions of obesity
and management practices in a UK population of leisure-horse owners and managers. J. Equine Vet. Sci.
2017, 53, 19–29. [CrossRef]
207. Jensen, R.B.; Danielsen, S.H.; Tauson, A.H. Body condition score, morphometric measurements and estimation
of body weight in mature Icelandic horses in Denmark. Acta Vet. Scand. 2016, 58, 59. [CrossRef]
208. Harker, I.J.; Harris, P.A.; Barfoot, C.F. The body condition score of leisure horses competing at an unaffiliated
championship in the UK. J. Equine Vet. Sci. 2011, 5, 253–254. [CrossRef]
209. Sánchez-Guerrero, M.J.; Ramos, J.; Valdés, M.; Valera, M. Prevalence, Environmental Risk Factors and
Heritability of Body Condition in Pura Raza Español Horses. Livest. Sci. 2019, 230, 103851. [CrossRef]
210. Bamford, N.J.; Potter, S.J.; Harris, P.A.; Bailey, S.R. Breed differences in insulin sensitivity and insulinemic
responses to oral glucose in horses and ponies of moderate body condition score. Domest. Anim. Endocrinol.
2014, 47, 101–107. [CrossRef]
211. Freestone, J.F.; Shoemaker, K.; Bessin, R.; Wolfsheimer, J.K. Insulin and glucose response following oral
glucose administration in well-conditioned ponies. Equine Vet. J. Suppl. 1992, 13–17. [CrossRef] [PubMed]
212. Jeffcott, L.B.; Field, J.R.; McLean, J.G.; O’Dea, K. Glucose tolerance and insulin sensitivity in ponies and
Standardbred horses. Equine Vet. J. 1986, 18, 97–101. [CrossRef] [PubMed]
213. Robie, S.M.; Janson, C.H.; Smith, S.C.; O’Connor, J.T., Jr. Equine serum lipids: Serum lipids and glucose in
Morgan and Thoroughbred horses and Shetland ponies. Am. J. Vet. Res. 1975, 36, 1705–1708. [PubMed]
214. Norton, E.M.; Schultz, N.E.; Rendahl, A.K.; Mcfarlane, D.; Geor, R.J.; Mickelson, J.R.; McCue, M.E. Heritability
of Metabolic Traits Associated with Equine Metabolic Syndrome in Welsh Ponies and Morgan Horses.
Equine Vet. J. 2019, 51, 475–480. [CrossRef]
215. Treiber, K.H.; Kronfeld, D.S.; Hess, T.M.; Byrd, B.M.; Splan, R.K.; Staniar, W.B. Evaluation of genetic and
metabolic predispositions and nutritional risk factors for pasture-associated laminitis in ponies. J. Am. Vet.
Med. Assoc. 2006, 228, 1538–1545. [CrossRef] [PubMed]
216. Lewis, S.L.; Holl, H.M.; Streeter, C.; Posbergh, C.; Schanbacher, B.J.; Place, N.J.; Mallicote, M.F.; Long, M.T.;
Brooks, S.A. Genomewide association study reveals a risk locus for equine metabolic syndrome in the
Arabian horse. J. Anim. Sci. 2017, 95, 1071–1079. [CrossRef] [PubMed]
Genes 2020, 11, 1378 28 of 29
217. Cash, C.M.; Fitzgerald, D.M.; Spence, R.J.; de Laat, M.A. Preliminary analysis of the FAM174A gene suggests
it lacks a strong association with equine metabolic syndrome in ponies. Domest. Anim. Endocrinol. 2020, 72,
106439. [CrossRef] [PubMed]
218. Roy, M.M.; Norton, E.M.; Rendahl, A.K.; Schultz, N.E.; McFarlane, D.; Geor, R.J.; Mickelson, J.R.; McCue, M.E.
Assessment of the FAM174A 11G allele as a risk allele for equine metabolic syndrome. Anim. Genet. 2020, 51,
607–610. [CrossRef]
219. Norton, E.; Schultz, N.; Geor, R.; McFarlane, D.; Mickelson, J.; McCue, M. Genome-Wide Association Analyses
of Equine Metabolic Syndrome Phenotypes in Welsh Ponies and Morgan Horses. Genes (Basel) 2019, 10, 893.
[CrossRef]
220. Norton, E.M.; Avila, F.; Schultz, N.E.; Mickelson, J.R.; Geor, R.J.; McCue, M.E. Evaluation of an HMGA2
variant for pleiotropic effects on height and metabolic traits in ponies. J. Vet. Intern. Med. 2019, 33, 942–952.
[CrossRef]
221. Martin, A.R.; Kanai, M.; Kamatani, Y.; Okada, Y.; Neale, B.M.; Daly, M.J. Clinical use of current polygenic risk
scores may exacerbate health disparities. Nat. Genet. 2019, 51, 584–591. [CrossRef] [PubMed]
222. Hayward, J.J.; Castelhano, M.G.; Oliveira, K.C.; Corey, E.; Balkman, C.; Baxter, T.L.; Casal, M.L.; Center, S.A.;
Fang, M.; Garrison, S.J.; et al. Complex disease and phenotype mapping in the domestic dog. Nat. Commun.
2016, 7, 10460. [CrossRef] [PubMed]
223. Dodman, N.H.; Karlsson, E.K.; Moon-Fanelli, A.; Galdzicka, M.; Perloski, M.; Shuster, L.; Lindblad-Toh, K.;
Ginns, E.I. A canine chromosome 7 locus confers compulsive disorder susceptibility. Mol. Psychiatry 2010,
15, 8–10. [CrossRef] [PubMed]
224. Hoeppner, M.P.; Lundquist, A.; Pirun, M.; Meadows, J.R.; Zamani, N.; Johnson, J.; Sundstrom, G.; Cook, A.;
FitzGerald, M.G.; Swofford, R.; et al. An improved canine genome and a comprehensive catalogue of coding
genes and non-coding transcripts. PLoS ONE 2014, 9, e91172. [CrossRef]
225. Halo, J.; Pendelton, A.L.; Shen, F.; Doucet, A.J.; Derrien, T.; Hitte, C.; Kirby, L.E.; Myers, B.; Sliwerska, E.;
Emery, S.; et al. Preprint—Long-read assembly of a Great Dane genome highlights the contribution of
GC-rich sequence and mobile elements to canine genomes. bioRxiv 2020. preprints. [CrossRef]
226. Bannasch, D.; Young, A.; Myers, J.; Truve, K.; Dickinson, P.; Gregg, J.; Davis, R.; Bongcam-Rudloff, E.;
Webster, M.T.; Lindblad-Toh, K.; et al. Localization of canine brachycephaly using an across breed mapping
approach. PLoS ONE 2010, 5, e9632. [CrossRef]
227. Friedenberg, S.G.; Meurs, K.M. Genotype imputation in the domestic dog. Mamm. Genome 2016, 27, 485–494.
[CrossRef]
228. Hayward, J.J.; White, M.E.; Boyle, M.; Shannon, L.M.; Casal, M.L.; Castelhano, M.G.; Center, S.A.;
Meyers-Wallen, V.N.; Simpson, K.W.; Sutter, N.B.; et al. Imputation of canine genotype array data using
365 whole-genome sequences improves power of genome-wide association studies. PLoS Genet. 2019,
15, e1008003. [CrossRef]
229. Gandolfi, B.; Alhaddad, H.; Abdi, M.; Bach, L.H.; Creighton, E.K.; Davis, B.W.; Decker, J.E.; Dodman, N.H.;
Ginns, E.I.; Grahn, J.C.; et al. Applications and efficiencies of the first cat 63K DNA array. Sci. Rep. 2018,
8, 7024. [CrossRef]
230. Kalbfleisch, T.S.; Rice, E.S.; DePriest, M.S.; Walenz, B.P.; Hestand, M.S.; Vermeesch, J.R.; O’Connell, B.L.;
Fiddes, I.T.; Vershinina, A.O.; Petersen, J.L.; et al. Preprint—EquCab3, an updated reference genome for the
domestic horse. bioRxiv 2018, 306928. [CrossRef]
231. McCue, M.E.; Bannasch, D.L.; Petersen, J.L.; Gurr, J.; Bailey, E.; Binns, M.M.; Distl, O.; Guerin, G.; Hasegawa, T.;
Hill, E.W.; et al. A high density SNP array for the domestic horse and extant Perissodactyla: Utility for
association mapping, genetic diversity, and phylogeny studies. PLoS Genet. 2012, 8, e1002451. [CrossRef]
232. Schaefer, R.J.; Schubert, M.; Bailey, E.; Bannasch, D.L.; Barrey, E.; Bar-Gal, G.K.; Brem, G.; Brooks, S.A.;
Distl, O.; Fries, R.; et al. Developing a 670k genotyping array to tag ~2M SNPs across 24 horse breeds.
BMC Genom. 2017, 18, 565. [CrossRef] [PubMed]
233. Schaefer, R.J.; McCue, M.E. Equine Genotyping Arrays. Vet. Clin. N. Am. Equine Pract. 2020, 36, 183–193.
[CrossRef]
234. Chassier, M.; Barrey, E.; Robert, C.; Duluard, A.; Danvy, S.; Ricard, A. Genotype imputation accuracy in
multiple equine breeds from medium- to high-density genotypes. J. Anim. Breed. Genet. 2018, 135, 420–431.
[CrossRef] [PubMed]
Genes 2020, 11, 1378 29 of 29
235. Samaha, G.; Beatty, J.; Wade, C.M.; Haase, B. The Burmese cat as a genetic model of type 2 diabetes in humans.
Anim. Genet. 2019, 50, 319–325. [CrossRef] [PubMed]
236. Brito-Casillas, Y.; Melian, C.; Wagner, A.M. Study of the pathogenesis and treatment of diabetes mellitus
through animal models. Endocrinol. Nutr. 2016, 63, 345–353. [CrossRef]
237. Srinivasan, K.; Ramarao, P. Animal models in type 2 diabetes research: An overview. Indian J. Med. Res.
2007, 125, 451–472.
238. Rimbault, M.; Ostrander, E.A. So many doggone traits: Mapping genetics of multiple phenotypes in the
domestic dog. Hum. Mol. Genet. 2012, 21, R52–R57. [CrossRef]
239. Shearin, A.L.; Ostrander, E.A. Leading the way: Canine models of genomics and disease. Dis. Model. Mech.
2010, 3, 27–34. [CrossRef]
240. Switonski, M. Dog as a model in studies on human hereditary diseases and their gene therapy. Reprod. Biol.
2014, 14, 44–50. [CrossRef]
241. Momozawa, Y.; Merveille, A.C.; Battaille, G.; Wiberg, M.; Koch, J.; Willesen, J.L.; Proschowsky, H.F.; Gouni, V.;
Chetboul, V.; Tiret, L.; et al. Genome wide association study of 40 clinical measurements in eight dog breeds.
Sci. Rep. 2020, 10, 6520. [CrossRef]
242. Sutter, N.B.; Eberle, M.A.; Parker, H.G.; Pullar, B.J.; Kirkness, E.F.; Kruglyak, L.; Ostrander, E.A. Extensive
and breed-specific linkage disequilibrium in Canis familiaris. Genome Res. 2004, 14, 2388–2396. [CrossRef]
243. Marsden, C.D.; Ortega-Del Vecchyo, D.; O’Brien, D.P.; Taylor, J.F.; Ramirez, O.; Vila, C.; Marques-Bonet, T.;
Schnabel, R.D.; Wayne, R.K.; Lohmueller, K.E. Bottlenecks and selective sweeps during domestication have
increased deleterious genetic variation in dogs. Proc. Natl. Acad. Sci. USA 2016, 113, 152–157. [CrossRef]
[PubMed]
244. Gurda, B.L.; Bradbury, A.M.; Vite, C.H. Canine and Feline Models of Human Genetic Diseases and Their
Contributions to Advancing Clinical Therapies. Yale J. Biol. Med. 2017, 90, 417–431. [PubMed]
245. Oh, A.; Pearce, J.W.; Gandolfi, B.; Ceighton, E.K.; Suedmeyer, W.K.; Selig, M.; Bosiack, A.P.; Castaner, L.J.;
Whiting, R.E.; Belknap, E.B.; et al. Early-Onset Progressive Retinal Atrophy Associated with an IQCB1
Variant in African Black-Footed Cats (Felis nigripes). Sci. Rep. 2017, 7, 43918. [CrossRef] [PubMed]
246. Lonker, N.S.; Fechner, K.; Wahed, A.A.E. Horses as a Crucial Part of One Health. Vet. Sci. 2020, 7, 28.
[CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
